NGM

San Francisco-based clinical-stage biopharmaceutical company NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) is seeing a lot of insider trading activity. The most recent was the purchase of around $13.3 million worth of shares by two of the company’s directors. The directors, David Goeddel and Column Group, own more than a 10% stake each in the company. On June 9, Column Group acquired 984,161 shares of NGM for $13.50 per share. The director now owns 2.65 million shares of the company. Meanwhile, Goeddel bought 951,684 NGM shares for $13.28 million. After the purchase, his stake in the company stands at 2.65 million shares.
https://www.tipranks.com/news/corporate-insiders-are-going-crazy-for-this-stock?utm_source=advfn.com&utm_medium=referral